Implicated in

Non-small cell lung carcinoma (NSCLC)
Note Mouse models suggest that EML4-ALK fusion might play an essential role in NSCLC carcinogenesis. EML4-ALK-fusion-transcript is detectable in a low amount (frequency between 2,7% and 6,7%) of NSCLC-samples and NSCLC-cell-lines. So far, the fusion-protein could only be detected by massspectrometry. Immunohistochemical detection of the Alk-protein in fusion-transcript-positive primary NSCLC-samples is contentious. Alk-inhibitors impede proliferation in EML4-ALKfusion positive lung cancer cell-lines. In experiments with transgenic mice, treatment with ALK-inhibitors resulted in reduced tumor mass. The role of EML4-ALK-fusion as a specific biomarker for NSCLC remains controversial. Disease NSCLC, frequency between 2,7% and 6,7%. Prognosis Controversially discussed. Limited informative because of low numbers studied so far. 
